If you blinked, you might have missed it. WORK Medical Technology Group Ltd (WOK) shares shot up nearly 70% on Tuesday, hitting $11.30, before crashing back down Wednesday. The stock was down about 80% in premarket trading, hovering around $1.33. That's the kind of whiplash that makes you check your brokerage app twice.
The Hangzhou-based company's rally came after it announced a deal with Shanghai Novabioplus Biotechnology Co., Ltd. The agreement is built around what the company calls a "Data-Model-Application" trinity — a fancy way of saying they're digitizing biopharmaceutical research. Management described it as a "significant milestone" for their digital ecosystem evolution.
Part of that evolution involves a BioToken framework, which aims to turn biopharma R&D outputs into digital assets. Think of it as tokenizing antibody sequences and enzyme designs, similar to how some companies tokenize real-world assets. It's a bold concept, but the market's reaction suggests traders are more focused on the short-term price action than the long-term vision.
Technically, WOK is a mess — in an interesting way. The stock is still trading 77.5% above its 20-day simple moving average of $1.64 and 115.8% above its 50-day SMA of $1.35. But it's also 99.8% below its 200-day SMA of $1,776.14. That last number isn't a typo — the stock once traded at those levels, and it's a reminder of how far it's fallen.
The real story is momentum. The relative strength index (RSI) is at 96.77, which is deep into overbought territory. Anything above 70 is considered overbought, so 96.77 is basically screaming "profit-taking time." And that's exactly what we're seeing.
The moving averages tell a mixed story: the 20-day SMA is above the 50-day SMA, which is a bullish near-term signal. But the 50-day SMA is still below the 200-day SMA, a bearish longer-term pattern known as a "death cross." So the short-term trend is up, but the long-term trend is still down.
Key levels to watch: resistance at $3 and support at $1.99. If the stock holds above $1.99, it might stabilize. If it breaks below, things could get uglier. The stock is currently near its 52-week low of $0.19, so there's plenty of room to fall.
For now, it's a classic case of a news-driven spike followed by a brutal correction. Traders who got in early might have locked in gains, but latecomers are feeling the pain. As always, volatility cuts both ways.
